Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bitolterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bitolterol SCHEMBL28134 | 1.00 | LMNA (0.54) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| Bitolterol SCHEMBL28133 | 1.00 | LMNA (0.54) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| Bitolterol SCHEMBL30929319 | 1.00 | LMNA (0.54) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| Bitolterol SCHEMBL30777231 | 1.00 | LMNA (0.54) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| Bitolterol SCHEMBL11286987 | 0.99 | ADRB2 (0.55) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| Bitolterol SCHEMBL4371 | 0.95 | LMNA (0.50) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| Bitolterol SCHEMBL4372 | 0.95 | LMNA (0.50) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| SCHEMBL20169505 | 0.92 | LMNA (0.46) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| Hydrochloric Acid SCHEMBL11276480 | 0.92 | ADRB2 (0.48) | LMNAHIF1AALDH1A1CYP3A4ADRB2 | |
| SCHEMBL11277082 | 0.92 | LMNA (0.47) | LMNAHIF1AALDH1A1CYP3A4ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829127-A | Low pH and low toxicity therapeutic materials for treating respiratory disease patients effective against at least one pathogen | TYGRUS有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-122094953-A | 1, 3-Dihydro-2H-pyrrolo [3,4-c ] quinoline derivatives as cGAS inhibitors for the treatment of inflammatory and/or autoimmune diseases | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250339413-A1 | COMBINATIONS OF MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | GLAXO GROUP LIMITED (GB) | 2025-08-26 | — | — | US | disclosed |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4578502-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | Glaxo Group Limited (GB) | 2025-07-02 | — | — | EP | disclosed |
| CN-120202206-A | Cyclic benzimidazole derivatives as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| CN-114072393-B | 3-Amino-4H-benzo [ E ] [1,2,4] thiadiazine 1, 1-dioxide derivatives as MRGX2 inhibitors | 索伦特治疗有限责任公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120051456-A | Substituted pyridone GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| CN-116444506-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11672818-B2 | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-06-13 | — | — | US | disclosed |
| CN-110678467-B | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-116157688-A | Methods for treating exacerbations of inflammatory respiratory diseases | 基因泰克公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-27 | — | — | US | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| US-20220047565-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LTD (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885LMNA 916/4885HIF1A 1484/4885 |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885LMNA 3264/4885HIF1A 3888/4885 |
| US-20250339413-A1 | COMBINATIONS OF MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885LMNA 3447/4885HIF1A 3925/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | ADRB2 40/4885LMNA 3691/4885HIF1A 630/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885LMNA 916/4885HIF1A 1484/4885 |
| US-11672818-B2 | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto | NOS1, NOS2, NOS3 | ADRB2 715/4885LMNA 3685/4885HIF1A 671/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885LMNA 916/4885HIF1A 1484/4885 |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CRH, HRH1, IL5 | ADRB2 40/4885LMNA 3691/4885HIF1A 630/4885 |
| US-20220047565-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRNB2, ADRA2A | ADRB2 1/4885LMNA 3280/4885HIF1A 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.